New drug cocktail aims to stop cervical cancer return
NCT ID NCT07368985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two years to see if the cancer progresses. The study also tracks side effects to assess safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and lenvatinib
- What this could lead to
- If successful, this combination could improve the chance of keeping cervical cancer from coming back for at least two years after standard treatment.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be definitive. The drugs can cause side effects like high blood pressure, fatigue, and immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE CERVIX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erasmus MC
Rotterdam, South Holland, 3015 GD, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.